SIC
TVRD

SJS Investment Consulting’s Tvardi Therapeutics TVRD Stock Holding History

SJS Investment Consulting’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2 Hold
1
– – ﹤0.01% 2884
2026
Q1 		$4 Buy
+1
New +$4 ﹤0.01% 2461
2023
Q2 		– Sell
-8
Closed -$1.47K – 1628
2023
Q1 		$1.47K Hold
8
– – ﹤0.01% 713
2022
Q4 		$3.22K Hold
8
– – ﹤0.01% 455
2022
Q3 		$3K Buy
+8
New +$2.9K ﹤0.01% 412
2022
Q1 		$4K Hold
8
– – ﹤0.01% 469
2021
Q4 		$4K Buy
+8
New +$4.02K ﹤0.01% 448

Other funds holding TVRD

SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AFG
American Financial Group Cincinnati, Ohio $284M AUM 12.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return

SJS Investment Consulting's TVRD Position: Q2 2026 in Review

SJS Investment Consulting held its Tvardi Therapeutics (TVRD) position steady in Q2 2026 at 1 share worth $2. The position accounts for ﹤0.01% of the portfolio, ranked #2884.

SJS Investment Consulting first reported a position in TVRD in Q4 2021 and has held it in 7 quarters since. The position peaked at $4K in Q1 2022. 57 funds tracked by Wall St. Rank hold TVRD as of Q2 2026.

  • SJS Investment Consulting held 1 share of Tvardi Therapeutics worth $2 as of Q2 2026.
  • SJS Investment Consulting left its Tvardi Therapeutics share count unchanged in Q2 2026.
  • Tvardi Therapeutics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #2884 holding.
  • SJS Investment Consulting first reported a position in Tvardi Therapeutics in Q4 2021 and has held it in 7 quarters since.
  • SJS Investment Consulting's Tvardi Therapeutics position peaked at $4K in Q1 2022.
  • 57 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.